Press "esc" to clear
Go to Advanced Search

Showing results

110 of 114

Article ID: 692594

Ludwig Scientists Share New Findings on Personalized Cancer Treatments, Immunotherapy and the Tumor Microenvironment at 2018 AACR Annual Meeting

Ludwig Cancer Research

Ludwig Cancer Research released today the full scope of findings to be presented by Ludwig researchers at this year’s American Association for Cancer Research (AACR) Annual Meeting in Chicago, Ill., April 14-18, 2018. Research conducted by more than 100 Ludwig scientists will be presented in symposiums, plenaries, town meetings, education sessions and poster sessions.

Released:
11-Apr-2018 4:00 PM EDT
EXPERT AVAILABLE
Open in New Tab
Comment
LanaAlexGeorge.png
  • Embargo expired:
    11-Apr-2018 2:00 PM EDT

Article ID: 692575

Ludwig Researchers Devise and Test Pioneering Personalized Cancer Vaccine for Ovarian Cancer

Ludwig Cancer Research

A Ludwig Cancer Research study has shown that an entirely new type of personalized cancer vaccine induces novel, potent and clinically effective immune responses in patients receiving a combination of standard therapies for recurrent, stage III and IV ovarian cancer.

Released:
10-Apr-2018 6:00 PM EDT
EXPERT AVAILABLE
Open in New Tab
Comment
HarariCoukos.png

Article ID: 691032

Ludwig Study Extends the Potential for Personalized Immunotherapy to a Large Variety of Cancers

Ludwig Cancer Research

A Ludwig Cancer Research study shows that ovarian cancer, which has proved resistant to currently available immunotherapies, could be susceptible to personalized immunotherapy. Led by Ludwig Lausanne investigator Alexandre Harari and George Coukos, director of the Ludwig Institute for Cancer Research, Lausanne, the study shows that ovarian tumors harbor highly reactive killer T cells—which kill infected and cancerous cells—and demonstrates how they can be identified and selectively grown for use in personalized, cell-based immunotherapies.

Released:
15-Mar-2018 6:00 AM EDT
EXPERT AVAILABLE
Open in New Tab
Comment
TokerImagetoUse.jpg

Article ID: 687056

Ludwig Researchers Uncover Mechanism Behind a Metabolic Vulnerability of Certain Breast Cancers

Ludwig Cancer Research

Many cancer cells are relatively sensitive to the deprivation of an essential amino acid known as methionine. Now, a Ludwig Cancer Research study published in the journal Science Signaling and led by Alex Toker, an investigator in the Ludwig Center at Harvard, has elucidated one mechanism behind that dependency.

Released:
19-Dec-2017 2:00 PM EST
EXPERT AVAILABLE
Open in New Tab
Comment
DonCleveland.png

Article ID: 686082

Ludwig Cancer Research Scientist Don Cleveland Wins Breakthrough Award

Ludwig Cancer Research

Ludwig Cancer Research extends its warmest congratulations to Don Cleveland, who has been a Member of the Ludwig Institute for Cancer Research since 1995 and today was awarded the prestigious Breakthrough Prize.

Released:
3-Dec-2017 8:00 PM EST
EXPERT AVAILABLE
Open in New Tab
Comment
Ralph.jpg

Article ID: 685643

Ludwig Researchers Unravel Novel Mechanism by Which Tumors Grow Resistant to Radiotherapy

Ludwig Cancer Research

A Ludwig Cancer Research study has uncovered a key mechanism by which tumors develop resistance to radiation therapy and shown how such resistance might be overcome with drugs that are currently under development.

Released:
23-Nov-2017 9:00 AM EST
EXPERT AVAILABLE
Open in New Tab
Comment

Article ID: 685033

Ludwig Scientists Share Findings on Development and Treatment of Glioblastoma at the 2017 Society for Neuro-Oncology Annual Meeting

Ludwig Cancer Research

Ludwig Cancer Research has released the scope of its participation at this year’s Annual Meeting and Education Day of the Society for Neuro-Oncology in San Francisco, California, November 16-19.

Released:
13-Nov-2017 9:00 AM EST
EXPERT AVAILABLE
Open in New Tab
Comment

Article ID: 684974

Ludwig Researchers Uncover Novel Mechanism by Which Tumors Evade a Variety of Cancer Immunotherapies

Ludwig Cancer Research

A Ludwig Cancer Research study led by Benoit Van den Eynde, Director of Ludwig Brussels, has identified a novel mechanism by which tumors of the aggressive skin cancer melanoma can resist cancer immunotherapy.

Released:
10-Nov-2017 9:00 AM EST
EXPERT AVAILABLE
Open in New Tab
Comment

Article ID: 684689

Ludwig Scientists Share Insights on Immunotherapy Research at the 2017 Society for Immunotherapy of Cancer Annual Meeting

Ludwig Cancer Research

Ludwig Cancer Research has released the scope of its participation at the 2017 Society for Immunotherapy of Cancer (SITC) Annual Meeting in National Harbor, Maryland, November 8-12.

Released:
6-Nov-2017 3:45 PM EST
EXPERT AVAILABLE
Open in New Tab
Comment

Article ID: 681318

Ludwig Scientists Discover Complex Axis of Immune Suppression Exploited by Cancers

Ludwig Cancer Research

A Ludwig Cancer Research study has uncovered a new mechanism by which cancer cells evade destruction by the immune system. The paper, led by Camilla Jandus of the Lausanne Branch of the Ludwig Institute for Cancer Research, describes how immune cells known as group 2 innate lymphoid cells (ILC2s) are recruited by leukemic cells to suppress an essential anticancer immune response.

Released:
19-Sep-2017 9:00 AM EDT
EXPERT AVAILABLE
Open in New Tab
Comment

Showing results

110 of 114





Chat now!